Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17652080 | 0.87 | KDM4E (0.37) | TYMSKDM4EALDH1A1 | |
| SCHEMBL17652035 | 0.82 | LMNA (0.35) | TYMSKDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL19253836 | 0.81 | TYMS (0.34) | TYMSKDM4EALDH1A1 | |
| SCHEMBL19253834 | 0.77 | MPO (0.39) | TYMS | |
| SCHEMBL25815335 | 0.74 | KCNA5 (0.36) | KDM4EKMT2ASMN1; SMN2TSHRMEN1 | |
| SCHEMBL17652009 | 0.73 | KMT2A (0.35) | TYMSKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL17652022 | 0.71 | CHUK (0.43) | TYMSKDM4EALDH1A1 | |
| SCHEMBL25388131 | 0.70 | HPGD (0.35) | TYMSKDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL25390339 | 0.69 | MAPT (0.33) | KDM4EALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL25389586 | 0.67 | MEN1 (0.38) | TYMSKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518765-B2 | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | THE PROVOST, THE FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2022-12-06 | — | — | US | disclosed |
| US-11229652-B2 | Treatments for autoimmune disease | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2022-01-25 | — | — | US | disclosed |
| US-20210024529-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2021-01-28 | — | — | US | disclosed |
| US-10793572-B2 | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | THE PROVOST FELLOWS FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2020-10-06 | — | — | US | disclosed |
| EP-3201198-B1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST FELLOWS FOUND SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIV (IE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3200798-B1 | TREATMENTS FOR AUTOIMMUNE DISEASE | THE PROVOST FELLOWS FOUND SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIV T (IE) | 2019-05-22 | — | — | EP | disclosed |
| US-20180256583-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2018-09-13 | — | — | US | disclosed |
| US-20170258797-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2017-09-14 | — | — | US | disclosed |
| US-20170240553-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST FELLOWS FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2017-08-24 | — | — | US | disclosed |
| EP-3200798-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth (IE) | 2017-08-09 | — | — | EP | disclosed |
| EP-3201198-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth (IE) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016050806-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016050804-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240553-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | TYMS, DPYD, C5 | TYMS 1/4885KDM4E 550/4885ELANE 3335/4885 |
| US-11518765-B2 | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | TYMS, C5, HRH3 | TYMS 1/4885KDM4E 541/4885ELANE 3856/4885 |
| US-20180256583-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | QTRT1, QTRT2, HPRT1 | TYMS 20/4885KDM4E 987/4885ELANE 1760/4885 |
| US-10793572-B2 | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | TYMS, DPYD, C5 | TYMS 1/4885KDM4E 550/4885ELANE 3335/4885 |
| US-20210024529-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | TYMS, C5, HRH3 | TYMS 1/4885KDM4E 541/4885ELANE 3856/4885 |
| US-20170258797-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | QTRT1, QTRT2, HPRT1 | TYMS 20/4885KDM4E 987/4885ELANE 1760/4885 |
| US-11229652-B2 | Treatments for autoimmune disease | QARS1, QTRT1, QTRT2 | TYMS 6/4885KDM4E 608/4885ELANE 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.